New therapeutic approaches for the treatment of hypertriglyceridemia.
Herz
; 47(3): 220-227, 2022 Jun.
Article
em En
| MEDLINE
| ID: mdl-35451595
ABSTRACT
Patients with hypertriglyceridemia (>â¯150â¯mg/dl) have an increased risk for atherosclerotic cardiovascular disease, and those with severe hypertriglyceridemia (>â¯880â¯mg/dl) also for pancreatitis. The currently available medications to decrease triglyceride levels, such as fibrates, statins, and omega3 fatty acids, are in many cases not able to achieve normal triglyceride levels. Therefore, new drugs are in development to address this unmet need. Recently, icosapent ethyl, a purified formulation of the omega-3-fatty acid eicosapentaenoic acid, was approved in Germany for the reduction of cardiovascular events in patients with hypertriglyceridemia and established cardiovascular disease or with diabetes and other risk factors on top of statins. Other new drugs in development are the more selective peroxisome proliferator-activated receptor α (PPARα) modulator, pemafibrate, already approved for the treatment of hypertriglyceridemia in Japan, and inhibitors of ApoC-III and angiopoietin-like 3 (ANGPTL3) in the form of antisense oligonucleotides or siRNAs or fully human monoclonal binding antibodies. Apolipoprotein C-III and ANGPTL3 protein seem to be quite promising targets based on solid genetic data. Larger studies of long duration, many of them currently ongoing, are needed to establish the role these medications will play in the treatment of hypertriglyceridemia in clinical practice.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Hipertrigliceridemia
/
Inibidores de Hidroximetilglutaril-CoA Redutases
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Herz
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Alemanha